Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

The Change History for BARDA BAA-23-100-SOL-00004 includes two amendments: Amendment 1 (Nov 9, 2023) made extensive updates to overview information, proposal instructions, and specific areas of interest, while Amendment 2 (Dec 22, 2023) specifically suspended Area of Interest 9.4 regarding COVID-19 Monoclonal Antibody Therapeutics for Treatment. Additionally, Amendment 1 also introduced new updates for diagnostics and medical countermeasures and suspended Area of Interest #11 related to COVID-19 immune assays. Overall, these amendments reflect ongoing adjustments to the program's objectives and submission processes.

The Office of Biomedical Advanced Research and Development Authority (BARDA) released Amendment 2 for its Broad Agency Announcement (BAA-23-100-SOL-00004), aiming to solicit proposals for advanced research and development of medical countermeasures (MCMs) to address threats from chemical, biological, radiological, and nuclear (CBRN) agents, among others. The BAA emphasizes a streamlined application process with three stages and encourages proposals from all responsible sources, including prioritized support for Historically Black Colleges and Minority Institutions. The amendment outlines specific areas of interest, eligibility criteria, and evaluation factors, focusing on accelerating the development of innovative MCMs while ensuring compliance with federal regulations.

Amendment 1 to the BARDA BAA-23-100-SOL-00004 document, dated November 9, 2023, includes comprehensive updates to various sections such as the Overview Information, Background, Development Objectives, and Proposal Instructions. Notable changes include new or updated areas of interest related to burn and blast medical countermeasures, diagnostics for biothreat agents, and the introduction of COVID-19 monoclonal antibody therapeutics while suspending the COVID-19 immune assay development topics. Additionally, the application process and submission instructions have been revised to reflect these changes.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has released Amendment 1 to its Broad Agency Announcement (BAA-23-100-SOL-00004), aimed at accelerating research and development of Medical Countermeasures (MCMs) in response to health emergencies, including threats from CBRN agents and infectious diseases. This BAA invites a wide range of Offerors, including private sector, academic institutions, and minority-owned businesses, to submit proposals that align with specified areas of interest such as vaccines, therapeutics, and diagnostics, with an emphasis on technological maturity and the possibility of multiple awards based on merit and available funding. The application process consists of three stages: pre-submission calls, market research abstracts, and detailed proposals, culminating in evaluations based on the scientific and technical merits, relevance to agency objectives, and cost considerations.

The Biomedical Advanced Research and Development Authority (BARDA) has released a new Broad Agency Announcement (BAA) (BAA-23-100-SOL-00004) on September 26, 2023, aimed at accelerating research and development of medical countermeasures (MCMs) for various public health threats, including chemical, biological, radiological, nuclear, and infectious diseases. This BAA emphasizes the enhancement of public-private partnerships to improve the development timeline of MCMs and encourages proposals from diverse entities, including academic institutions and small businesses, stating a preference for scalable innovations addressing national emergencies. The document details a structured three-stage application process for interested parties, alongside specific areas of interest for R&D, proposal submission guidelines, and evaluation criteria.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has issued the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, dated September 26, 2023, to solicit proposals for advanced research and development (R&D) of Medical Countermeasures (MCMs) addressing Chemical, Biological, Radiological, Nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. This BAA aims to accelerate partnerships, enhance responsiveness, and modernize the award process for developing life-saving MCMs critical for national health security. Eligible offerors, which include private organizations, government laboratories, and academic institutions, may submit proposals through a three-stage process: preliminary inquiries and market research, followed by detailed proposals based on favorable assessments. Technological maturity, regulatory compliance, and manufacturing standards are pivotal to the evaluation criteria. The announcement emphasizes BARDA's commitment to improving public health preparedness, leveraging public-private partnerships to expedite the development of MCMs, and addressing gaps highlighted during public health emergencies like COVID-19. Interested parties are encouraged to monitor updates on platforms such as SAM.gov and Grants.gov, with an open submission period running until September 25, 2028.

The Office of Biomedical Advanced Research and Development Authority (BARDA) issued the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 to solicit proposals for advanced research and development (R&D) of medical countermeasures (MCMs) against public health threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, emerging infectious diseases, and pandemic influenza. The BAA aims to enhance efficiency in partnering and responsiveness to the increasing demands for MCM development. It outlines eligible offerors, including private sector entities, academic institutions, and encourages participation from historically marginalized groups. Proposals must address predetermined Areas of Interest (AOIs) for MCMs, covering various aspects of development, regulatory approach, and manufacturing standards. The application process consists of three stages: initial inquiries, a Market Research Abstract submission, and a detailed proposal. Evaluations will consider scientific merit, relevancy, and the offeror's capabilities, with awards depending on proposal quality and available funding. The BAA supports a coordinated governmental effort for health security, emphasizing public-private partnerships to tackle urgent health threats efficiently.

The Office of Biomedical Advanced Research and Development Authority (BARDA) issued Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 to solicit proposals for advanced research and development (R&D) of Medical Countermeasures (MCMs) targeting chemical, biological, radiological, and nuclear threats as well as emerging infectious diseases. This BAA is intended to accelerate the development of MCMs through innovative public-private partnerships, particularly in light of lessons learned from the COVID-19 pandemic. The announcement outlines several areas of interest for R&D, including vaccines, therapeutics, diagnostics, and manufacturing processes, with an emphasis on technological maturity and the ability to achieve FDA approvals. The application process is structured in three stages: pre-submission calls for guidance, submission of a Quad Chart and Market Research Abstract, and a full proposal invitation based on favorable assessment of Stage 2 submissions. Awards may be in various contract forms, with multiple awards anticipated based on scientific merit and funding availability. Overall, this BAA reflects BARDA’s commitment to enhancing national health security through effective MCM development against existing and emergent public health threats.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has issued Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 to solicit proposals for advanced research and development (R&D) of medical countermeasures (MCMs) against various public health threats, including chemical, biological, radiological, and nuclear agents, pandemic influenza, and emerging infectious diseases. The BAA aims to modernize and streamline the proposal process to enhance responsiveness and efficiency within its partnerships with private and public sectors. Eligible offerors include diverse organizations and academic institutions, emphasizing inclusion of historically marginalized groups. The submission process consists of three stages: preliminary market research discussions, detailed abstract submissions, and formal proposals, focusing on the required technological maturity and regulatory strategies for the proposed MCMs. The document outlines expectations regarding proposal handling, submission formats, and evaluation criteria, which include scientific relevance, technical merit, and capabilities of the offerors. BARDA emphasizes the need for robust partnerships to tackle health security issues effectively, and encourages participation through a TechWatch program to optimize alignment with its strategic objectives.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has issued a Broad Agency Announcement (BAA-23-100-SOL-00004) to solicit proposals for the advanced research and development of Medical Countermeasures (MCMs) addressing threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, along with pandemic influenza and emerging infectious diseases. This BAA aims to catalyze innovation and accelerate the development process, particularly in light of lessons learned from the COVID-19 pandemic. Eligible offerors include private sector organizations, government laboratories, academic institutions, and various small business concerns. The submission process occurs in three stages: initial inquiries, submission of a Quad Chart and Market Research Abstract, and a formal proposal for selected candidates. Multiple awards are anticipated based on the scientific merit of the proposals and available funding. Key areas of interest span developments in CBRN vaccines, antivirals, diagnostics, and therapeutics. The objective is to enhance the knowledge and technological maturity of potential MCMs while ensuring that regulatory standards and product quality are maintained throughout the development process. By leveraging public-private partnerships, BARDA seeks to improve national preparedness against public health emergencies.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has issued the Broad Agency Announcement (BAA) BAA-23-100-SOL-00004 to solicit proposals for advanced research and development (R&D) of Medical Countermeasures (MCMs) against public health threats, including CBRN agents and emerging infectious diseases. The BAA focuses on fostering innovation and public-private partnerships to expedite MCM development and regulatory approval. Eligible participants include private sector organizations, government labs, and academic institutions, with encouragement for diverse representations, such as minority institutions and small businesses. The solicitation outlines a three-stage application process: Stage 1 involves pre-submission calls for initial guidance, Stage 2 requires submission of a Quad Chart and Market Research Abstract, and Stage 3 entails full proposal submission. It emphasizes the importance of compliance with regulations and reporting requirements, and it allows various award types, including contracts and grants. The deadline for submissions is September 25, 2028. This initiative reflects BARDA's commitment to enhancing national preparedness for health crises and aligns with strategic plans for health security and biodefense.

The Office of Biomedical Advanced Research and Development Authority (BARDA) issued Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, providing a framework for soliciting proposals on the advanced research and development (R&D) of Medical Countermeasures (MCMs) against chemical, biological, radiological, nuclear threats, and emerging infectious diseases, including pandemic influenza. The BAA aims to modernize partnerships and streamline the development process, allowing for multiple awards based on scientific merit and program priorities. Eligible offerors include a wide array of organizations, encouraging participation from historically marginalized groups. The application process is structured in three stages: pre-submission calls with the technical points of contact, followed by a Quad Chart and Market Research Abstract, and culminating in full proposals. Proposals will be evaluated based on technical merit, scientific relevance, and the proposer's qualifications. Key areas of interest include developing vaccines, antivirals, diagnostics, and therapeutics. Emphasis is placed on leveraging existing partnerships to expedite MCM development with a focus on supporting public health preparedness through innovative solutions and timely responsiveness to emerging threats.

The Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, Amendment 3, issued March 29, 2024, outlines a multi-stage application process for advanced research and development (R&D) of Medical Countermeasures (MCMs). This BAA aims to accelerate partnering and improve responsiveness in developing MCMs for chemical, biological, radiological, and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases. It solicits proposals for R&D across twelve areas of interest (AOIs), including vaccines, antivirals, antimicrobials, and diagnostics. The application process involves a pre-submission call, a Quad Chart and Market Research Abstract, and a full proposal. The document details program management, regulatory, and development/manufacturing approaches for various MCM types. All submissions are electronic, and multiple award types, including cost-reimbursement contracts, grants, and cooperative agreements, are anticipated.

The document outlines the change history for BARDA BAA-23-100-SOL-00004, detailing seven amendments made between November 2023 and March 2026. These amendments introduce significant updates across various sections, including background information, reporting requirements, special considerations, and proposal instructions. A major focus of the changes involves the modification, suspension, addition, or reopening of numerous 'Areas of Interest' (AOIs). Key AOIs affected include CBRN Antivirals and Antitoxins, Antimicrobials, Diagnostics, IEID Therapeutics, CBRN Vaccines, Radiological/Nuclear Threat Medical Countermeasures, Chemical Medical Countermeasures, Burn and Blast Medical Countermeasures, IEID Vaccines, and ImmuneChip+. Specific updates address topics such as anthrax antitoxins, filovirus antivirals, MDR bacteria, biothreat agent diagnostics, influenza testing, broad-spectrum antiviral therapeutics, botulism antitoxins, Sudan and Marburg virus vaccines, acute radiation syndrome, and burn/blast traumatic injuries. The amendments also introduce new requirements like the ASPR Public Access Policy and a Supply Chain Risk Assessment, while suspending certain AOIs like Needle-Free Technologies and COVID-19 Monoclonal Antibody Therapeutics. The document reflects an ongoing effort to refine and update the BAA's scope and requirements to align with evolving public health and biodefense priorities.

The Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, Amendment 6, outlines an updated process for soliciting proposals for advanced research and development (R&D) of Medical Countermeasures (MCMs). This BAA aims to accelerate partnering and improve responsiveness to public health emergencies, including chemical, biological, radiological, and nuclear (CBRN) incidents, pandemic influenza, and emerging infectious diseases. The application process involves three stages: a pre-submission call, a Quad Chart and Market Research Abstract submission, and a full proposal submission. BARDA encourages participation from diverse entities, emphasizing the development of MCMs towards FDA approval. The document details specific R&D areas of interest, technological maturity requirements, and various award types, including contracts, grants, and cooperative agreements. Special considerations for program management, regulatory, and manufacturing approaches are also provided.

The document outlines updates to the BARDA Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, specifically detailing Amendment 6 issued on May 29, 2025. This amendment includes revisions across various sections, including the introduction, background, technical objectives, proposal instructions, and evaluation criteria for proposals related to medical countermeasures against chemical, biological, radiological, and nuclear threats. Key changes include updates to eligible offerors, specific areas of interest (AOIs) such as CBRN vaccines, diagnostics, and therapeutics, as well as additions like definitions and program relevance factors for proposal evaluation. Several AOIs have updated introductory paragraphs and specific objectives, while some, like "Needle-Free Technologies" and others, have been suspended or rescinded. Additionally, prior amendments (1-5) have laid the groundwork for enhancing proposal guidelines, introducing supply chain risk assessments, and addressing emerging pathogens, including updates related to Covid-19 therapeutics. The document reflects BARDA's commitment to advancing public health preparedness through targeted guidance and evaluation of innovative proposals.

The Office of Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, Amendment 6, issued on May 29, 2025, modernizes BARDA's approach to accelerate the development and procurement of Medical Countermeasures (MCMs) for public health emergencies. This BAA seeks proposals for advanced research and development (R&D) of MCMs against chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The application process involves three stages: a pre-submission call, a Quad Chart and Market Research Abstract submission, and a full proposal. Eligibility is open to all responsible sources, including private organizations, government laboratories, and academic institutions, with an emphasis on various small business concerns. Proposals are evaluated based on program relevance, scientific/technical merits, and offeror capabilities. The BAA outlines specific R&D areas of interest, including CBRN vaccines, antivirals, antimicrobials, radiological/nuclear countermeasures, chemical countermeasures, burn and blast countermeasures, diagnostics, IEID vaccines and therapeutics, and ImmuneChip+. It also details programmatic, regulatory, and manufacturing approaches, reporting requirements, and special considerations for sensitive information and compliance.

The document outlines Amendment 5 of the BARDA Broad Agency Announcement (BAA-23-100-SOL-00004), detailing significant updates to various sections regarding development and technical objectives in medical countermeasures. Key revisions include updates to the Detection, Diagnostics, and Devices Infrastructure (DDDI) Division's language, enhancements to the Manufacturing Development Activities, and the inclusion of new attachments such as Supply Chain Risk Assessment and specific procurement guidelines for synthetic nucleic acids. Suspensions of several Areas of Interest (AOIs) related to needle-free technologies, COVID-19 therapeutics, and some diagnostics are noted. Additionally, various AOIs covering CBRN vaccines, antivirals, chemical countermeasures, and burn and blast medical countermeasures received updates. The amendments aim to enhance proposal evaluation criteria, emphasizing supply chain risk assessments and the importance of diagnostics, especially concerning biothreat agents and antimicrobial resistance. Overall, the amendment underscores BARDA's ongoing commitment to advancing research and development in critical health responses and improving contractor eligibility standards through structured updates and evaluations.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has issued Amendment 5 to its Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, effective December 18, 2024. This BAA seeks proposals for advanced research and development (R&D) of Medical Countermeasures (MCMs) to address chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The announcement outlines a three-stage application process, beginning with optional pre-submission calls, followed by a mandatory Quad Chart and Market Research Abstract, and finally a full proposal submission by invitation. BARDA aims to accelerate partnering and improve responsiveness in MCM development. Eligible offerors include private sector organizations, government laboratories, and academic institutions. The BAA details various R&D areas of interest, technological maturity requirements, and potential award types, including cost-reimbursement and firm-fixed-price contracts, grants, and Other Transaction agreements. Special considerations for sensitive information, security plans, and compliance with manufacturing standards are also highlighted.

The document outlines a series of amendments to the BARDA BAA-23-100-SOL-00004, which focuses on the development of diagnostics and therapeutics for biological threats and emergencies. It details changes made across four amendments from November 2023 to May 2024. Key areas of interest (AOIs) include updates to diagnostic tests for filovirus, bacterial antimicrobial resistance, and influenza, as well as advancements in medical countermeasures for diverse threats such as antimicrobial resistance and traumatic injuries. Specific amendments include updated technology readiness level (TRL) requirements and the suspension of outdated guidelines related to COVID-19 monoclonal antibodies. Overall, these amendments aim to refine research priorities, enhance proposal instructions, and clarify application processes to ensure robust responses to public health threats. The document serves as a guide for stakeholders involved in federal grants and proposals, emphasizing the need for adaptive strategies in medical research and development.

The Office of Biomedical Advanced Research and Development Authority (BARDA) has released Amendment 4 to its Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, effective May 31, 2024. This BAA seeks proposals for advanced research and development (R&D) of Medical Countermeasures (MCMs) against chemical, biological, radiological, nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases. The announcement outlines a three-stage application process, including pre-submission calls, Quad Chart and Market Research Abstract submissions, and full proposals. It details specific R&D Areas of Interest (AOIs) such as CBRN vaccines, antivirals, antimicrobials, radiological/nuclear/chemical countermeasures, burn/blast countermeasures, diagnostics, and emerging infectious disease treatments. The BAA emphasizes accelerating partnerships, improving responsiveness, and leveraging public-private collaborations to advance MCMs towards FDA approval. Eligible offerors include private sector organizations, government laboratories, and academic institutions, with multiple award types anticipated. Submissions are due by September 25, 2028.

The document outlines a series of amendments to the BARDA BAA-23-100-SOL-00004, detailing updates across various Areas of Interest (AOIs). Amendment 3, dated March 29, 2024, includes significant revisions to AOI 3 concerning antimicrobial resistance, AOI 5 related to chemical medical countermeasures, and AOI 6 focusing on burn and blast trauma management. New areas have been introduced, such as advanced imaging technologies, while some areas have been suspended or updated, particularly in diagnostics and trauma management. Amendment 2 from December 22, 2023, suspended a specific AOI related to COVID-19 monoclonal antibody therapeutics. Amendment 1, issued on November 9, 2023, includes updates to various sections of the overview information, submission process, and proposal instructions, as well as adding to or updating other AOIs, including therapeutics related to infectious diseases. These amendments highlight the evolving focus of BARDA on addressing current public health threats, including antimicrobial resistance and trauma care, indicating a proactive approach to research and development in medical countermeasures. The document serves as an update for potential applicants in the federal grants and RFPs context, ensuring alignment with ongoing and emerging health challenges.

This document outlines two amendments for the BARDA Broad Agency Announcement (BAA-23-100-SOL-00004). Amendment 1, issued on November 9, 2023, includes updates to various sections such as the overview of research opportunities, application processes, contract information, proposal instructions, and evaluation criteria. Noteworthy updates involve changes to Areas of Interest, including modifications to diagnostics related to influenza and biothreat agents, and the introduction of a new area on COVID-19 monoclonal antibody therapeutics for treatment. Amendment 2, released on December 22, 2023, suspends Area of Interest 9.4 for COVID-19 monoclonal antibody therapeutics. Additionally, it highlights the importance of the recent changes made to improve clarity and streamline submission processes for potential applicants in the medical countermeasures domain. The document serves as a vital resource for grant applicants and enhances the Department of Health and Human Services' efforts in improving public health responses. Overall, the amendments reflect a responsive and adaptive approach to evolving health threats and the need for timely updates in government-funded research.

The Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, Amendment 2, issued on December 22, 2023, is a solicitation for advanced research and development (R&D) of Medical Countermeasures (MCMs) against chemical, biological, radiological, and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases. The BAA outlines a three-stage application process: a pre-submission call with a Technical Point of Contact (POC), submission of a Quad Chart and Market Research Abstract, and a full proposal by invitation. BARDA aims to accelerate partnering, improve responsiveness, and decrease award times, supporting MCMs from early research through FDA approval. Eligible offerors include private organizations, government laboratories, and academic institutions, with encouragement for small and minority-owned businesses. The BAA details specific R&D areas of interest (AOIs) and emphasizes adherence to regulatory and manufacturing standards, including Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP).

The document details Amendment 1 (dated November 9, 2023) for the BARDA Broad Agency Announcement (BAA) BAA-23-100-SOL-00004, outlining significant updates across various sections concerning research and development opportunities. Key revisions include an updated overview of the application process, specific changes to proposal instructions, and adjustments in evaluation criteria related to past performance. Areas of interest have been updated, such as new requirements in medical countermeasures for burn and blast injuries, biothreat diagnostics, and COVID-19 therapeutics. Notably, Area of Interest #11 concerning COVID-19 immune assay development has been suspended. The updates aim to refine the submission process and enhance the alignment of projects with stated objectives, emphasizing BARDA's commitment to medical innovation and readiness. This amendment signifies the agency’s responsive approach to evolving public health challenges and the importance of adaptive measures in federal grant proposals.

BARDA BAA-23-100-SOL-00004 Amendment 1 outlines the Biomedical Advanced Research and Development Authority's (BARDA) Broad Agency Announcement for advanced R&D of Medical Countermeasures (MCMs) against CBRN agents, pandemic influenza, and emerging infectious diseases. This BAA, issued under FAR 6.102(d)(2)(i), modernizes BARDA's approach to accelerate partnering and MCM development. It is open to all responsible sources, including private sector, government, and academic entities, with specific eligibility requirements for FFRDCs and government entities. The application process involves three stages: a pre-submission call, a Quad Chart and Market Research Abstract, and a full proposal. The deadline for Stage 2 and 3 submissions is September 25, 2028. Proposals are sought across various Areas of Interest (AOIs) detailed in Part VIII, covering vaccines, antivirals, antimicrobials, radiological/nuclear, chemical, burn/blast medical countermeasures, diagnostics, and flexible therapeutics. The document specifies detailed requirements for program management, regulatory, and development/manufacturing approaches for different MCM types (small molecules/biologics, vaccines, diagnostics, respiratory protective devices). Award types may include Cost-Reimbursement or Firm-Fixed-Price contracts, grants, and cooperative agreements. All submissions must be electronic via the BARDA Digital Resources Portal, adhering to strict formatting guidelines.

The Biomedical Advanced Research and Development Authority (BARDA) issued BAA-23-100-SOL-00004, an updated Broad Agency Announcement (BAA) for advanced research and development (R&D) of Medical Countermeasures (MCMs). This BAA aims to accelerate partnering and improve responsiveness in developing MCMs against chemical, biological, radiological, nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The application process involves three stages: a pre-submission call, a Quad Chart and Market Research Abstract submission, and a full proposal. The BAA outlines specific R&D areas of interest, including CBRN vaccines, antivirals, antimicrobials, radiological/nuclear, chemical, and burn/blast medical countermeasures, diagnostics, and emerging infectious disease therapeutics and vaccines. It also details program management, regulatory, and manufacturing approaches for various product types, emphasizing compliance with FDA guidelines and manufacturing standards.